Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + olaparib + temozolomide
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the immune checkpoint inhibitor pembrolizumab, the PARP inhibitor olaparib, and the alkylating chemotherapy agent temozolomide. It is currently being evaluated in a Phase II clinical trial (NCT05188508) led by Memorial Sloan Kettering Cancer Center for the treatment of patients with recurrent glioma, specifically focusing on IDH-mutant cases and IDH-wildtype cases with homologous recombination deficiency (HRD). The therapeutic rationale involves a synergistic approach: temozolomide induces DNA damage, olaparib inhibits the repair of that damage (particularly effective in HRD-positive tumors), and pembrolizumab enhances the T-cell mediated immune response against the tumor cells. The regimen is administered in 21-day cycles, with pembrolizumab delivered intravenously and the other two agents administered orally.
- Other names
- Pembrolizumab, Olaparib, and Temozolomide combinationKeytruda + Lynparza + Temodar
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on pembrolizumab + olaparib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + olaparib + temozolomide.